Extended analysis of a phase 3 trial in 315 patients with HR+/HER2− advanced breast cancer and ESR1 mutation in ctDNA before progression: switching to camizestrant vs continuing aromatase inhibitor (both with CDK4/6 inhibitor) gave median PFS 16·8 vs 9·2 months (HR 0·45).
RCTn = 315
Turner et al. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial